Antimicrobials: An update on new strategies to diversify treatment for bacterial infections.

Alexander Fleming was one of the 100 most important people of the 20th century for his discovery of Penicillin '' It was the discovery that would change the course of history. The active ingredient in the mold, which Fleming named penicillin, turned out to be an infection-fighting agent of enormous potency'' A revolutionary development in science is a change in the way scientists perceive a certain idea or belief. The finding of Penicillin by Alexander Fleming in 1928 was a revolutionary development in the field of science. The discovery revolutionized the way infections were treated as well as impacted the scientific field, the medical field, the pharmaceuticals industry, and all humanity. Alexander Fleming's discovery of Penicillin sparked the development of antibiotics, which has continued to save People's lives since the revolution, making him a revolutionary figure. Despite the fact that Fleming was not only solely responsible for the revolutionary development, it was also his discovery of Penicillin that led to the development of antibiotics. In October 1945 Alexander Fleming, Howard Florey, and Ernest Chain each received an almost identical telegram from Stockholm, Sweden. The Nobel prize committee, these messages read, was pleased to inform the three British - based scientists that they had been awarded the Nobel prize for Medicine, for the discovery of Penicillin and its curative action in various disease1. This was not surprising news, In Fact, a year earlier, two major newspapers had informed their readers that Fleming would receive the prestigious award in 19442. Although reporters' stories were a year a hand of their time, they were right that the global scientific community had generally agreed that the world's first antibiotics were a landmark in medical history worthy of Nobel prize recognition. While the committee's decision to award the Nobel prize to the scientists who had developed penicillin was not controversial, the precise choice of whom to award the prize to was more fraught. The uncertainty arose because of the long and complicated process of drug development. The story began in 1928 when Alexander Fleming a Scottish bacteriologist working at St. Mary's Hospital Medical school in London, noticed that a specific strain of mold, Penicillium notatum, inhibited the growth of bacteria setting out to understand more about the mold s unusual properties, Fleming conducted additional experiments concluded that the antibiotics solution that he had made from the mold into a useable drug, convinced that further research on the substance would not be fruitful, Fleming turned to other matters. For a decade, Fleming's discovery attracted little attention then in 1938, two scientists working at the University of Oxford's Sir William Dunn School of Pathology. Howard Flory, an Australian Pathologist, and Ernest Chain, a German biochemist began researching a selection of antibacterial compounds. Over the next two years, chain and Florey, and their oxford colleagues experimented on Penicillium notatum. During that time, the scientists made several important discoveries and thwarted Fleming. By the spring of 1940, Florey and chain had developed a drug, which they mice. The following year, they carried out the first preliminary clinical trials on oxford. After the second world war, the battle for credit also acquired important national overtones. In telling the story of Penicillin's development, journalists and politicians incorporated the drug into celebratory narratives about national inventiveness, innovation, and character. In Britain and the united states' particularly myths of corporate ingenuity, economic opportunities missed and discoveries stolen would shape subsequent antibiotics development and the global production of Pharmaceuticals.

The yellow brick road to penicillin: a story of serendipity.

PENICILLINS AND STAPHYLOCOCCI: A HISTORICAL INTERACTION CRAIG H. STEFFEE* The development of beta-lactam antibiotics (penicillin and its contemporary cousins) is intertwined with the history of disease-producing staphylococci. Strains of staphylococci have been employed as laboratory models for the study of the biochemistry, mechanism of action, in vitro activity, and in vivo efficacy of beta-lactams since the "discovery" of penicillin in 1928. After the clinical introduction of penicillin in the early 1940s and its extensive use as a treatment for staphylococcal and other bacterial infections, the emergence of bacterial enzyme-mediated resistance in staphylococci inspired the chemical modification of pencillin to regain activity against resistant strains. The introduction ofthese new agents in the early 1960s again met with the development of resistant staphylococci. In the last two decades, the prominent role of Staphylococcus aureus in clinical infections has been supplemented by the emergence of related staphylococcal species (coagulase-negative staphylococci) as significant pathogens often highly resistant to antimicrobial therapy. In 1883, Sir Alexander Ogston described cluster-forming cocci whose resemblance to a cluster of grapes suggested the name "staphylo-" (Greek for "bunch of grapes") cocci [I]. Rosenbach isolated staphylococci in pure culture the subsequent year and distinguished between two colony types. Organisms appearing as orange-yellow colonies were termed Staphylococcus pyogenes aureus, and those growing as white colonies were named Staphylococcus pyogenes albus [2]. The aureus variant, recognized immediately as a major pathogen, is indeed a true species (Staphylococcus aureus), but the albus variant is actually a collection of The author thanks Benedict Wasilauskas and Richard Vance for advice and assistance, and Manson Meads, and Robert Prichard for reviewing the manuscript. *Student Box 2680, Bowman Gray School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157.© 1992 by The University of Chicago. AU rights reserved. 003 1-5982/92/3504-0792$0 1 .00 596 Craig H. Steffee ¦ Penicillins and Staphylococci species collectively known as "coagulase-negative staphylococci." At least 21 species have been distinguished within this group [3], but relatively few (primarily S. epidermidis) are isolated from human infections. The first reference to an in vitro bacterial-fungal interaction was made in 1871 by Sir John Burden-Sanderson, who observed that whereas liquid culture media exposed to air became turbid with growing bacteria , if a pénicillium mold happened to grow on the liquid surface no turbidity ensued [4]. Joseph Lister noted this observation and planned immediate clinical application, writing in 1872 that "should a suitable case present, I shall endeavor to employ Pénicillium glaucum and observe if the growth of the organisms be inhibited in the human tissues" [5]. There is some evidence that he did successfully treat the stubbornly infected wound of a young woman with an extract of "pénicillium," but he did not publish the results. Unpublished accounts from other investigators describe the ability of pénicillium culture extracts to inhibit the growth of virulent bacteria and to ameliorate infections in experimental animals and humans [4], but these trials were virtually ignored. Alexander Fleming, who is credited with the discovery of penicillin, was therefore not the first to observe interaction between residents of a culture dish, but he was the first to conduct extensive laboratory characterization of the substance he termed "penicillin" before attempting its clinical application. The events surrounding Alexander Fleming's discovery of penicillin in September 1928 were described to historians by a colleague, D. M. Pryce. Fleming was studying variations in the coloration of staphylococcal colonies that seemed to be related to virulence, color changes that only became apparent after several days of room-temperature incubation . In the process of describing his current experiments to Pryce, Fleming selected several culture plates from a Lysol-filled basin into which they had been discarded. Fleming had worked with many cultures that day, thus a few culture plates were situated above the level of the liquid antiseptic [4]. One such plate contained a contaminating mold whose presence seemed to be influencing the morphology of the surrounding colonies of staphylococci: colonies in proximity to the mold became transparent and seemed to be undergoing lysis [6]. This discovery has been described by MacFarlane as a remarkable conspiracy of several discrete chance events. Fleming...

Alexander Fleming's discovery of penicillin is one of the most significant breakthroughs in medical history, revolutionizing the treatment of bacterial infections and saving countless lives. This report chronicles Fleming's journey from his early life in rural Scotland to his pioneering work in bacteriology. It delves into his medical education and career, including his formative experiences during World War I that shaped his future research. The serendipitous discovery of penicillin in 1928, followed by the challenges of isolating and producing the antibiotic, is explored in detail. The report also highlights the crucial contributions of Howard Florey, Ernst Boris Chain, and Norman Heatley in developing penicillin into a widely usable therapeutic agent, particularly during World War II. Fleming's achievements were recognized with the Nobel Prize in 1945 and numerous other honors in Physiology/Medicine. His personal life, continued research, and lasting impact on medicine are also discussed, emphasizing the enduring legacy of his work in the ongoing development of antibiotics and the transformation of medical practices. This comprehensive overview underscores the importance of curiosity, perseverance, and collaboration in scientific discovery, inspiring future researchers.

Antimicrobial resistance (AMR) is emerging as one of the most significant threats to global public health, with the potential to reverse the medical advances achieved over the past century. Since Alexander Fleming's discovery of penicillin in 1928, antibiotics have been indispensable in treating bacterial infections, enabling safe surgical procedures, and extending life expectancy. However, the efficacy of these life-saving drugs is rapidly diminishing due to the widespread misuse and overuse of antibiotics in both human medicine and agriculture. AMR occurs when bacteria evolve mechanisms to withstand the effects of antibiotics, rendering standard treatments ineffective. The primary mechanisms of resistance include the reduction of drug uptake, modification of drug targets, enzymatic inactivation of drugs, and the active efflux of antibiotics out of bacterial cells. These resistant strains can spread through human contact, environmental reservoirs, and the food chain, exacerbated by the use of antibiotics in animal husbandry. The consequences of AMR are dire. Infections that were once easily treatable are becoming increasingly difficult and expensive to manage, leading to higher rates of morbidity and mortality. The financial burden on healthcare systems is substantial, with prolonged hospital stays, the need for more expensive drugs, and the requirement for more intensive care. To address this growing crisis, a multifaceted approach is essential. Stricter regulations on the use of antibiotics, both in healthcare settings and in agriculture, are critical to curbing the spread of resistance. Enhancing access to vaccines and promoting appropriate use of existing antibiotics can help prevent infections and reduce the need for antibiotic use. Additionally, international cooperation is crucial for monitoring and responding to AMR on a global scale. Investing in research and development of new antibiotics and alternative therapies is also imperative. Public awareness campaigns aimed at educating both healthcare professionals and the general public about the dangers of antibiotic misuse are essential for changing behaviour. Without these immediate and coordinated efforts, AMR could lead to a future where routine surgeries, chemotherapy, and even minor infections become life-threatening, effectively turning back the clock on modern medicine.

OPINION article Front. Microbiol., 20 August 2013Sec. Antimicrobials, Resistance and Chemotherapy Volume 4 - 2013 | https://doi.org/10.3389/fmicb.2013.00240

Sir Alexander Fleming's discovery of penicillin and Wilhelm Roentgen's detection of X rays are two of the more famous illustrations of research findings coming about accidentally. Fleming and Roentgen each was working in the general field of his major breakthrough when a significant disclosure occurred quite fortuitously. Results presented in this article also came about somewhat unintentionally. While studying the benefits of investment in cooperative education, positive outcomes in completing a baccalaureate degree with a specialization in nursing, turned up. A study of Lehman College alumni (1980-1985) revealed that nursing students fared better in the labor market upon graduation than did their nonnursing counterparts. This article examines several of the employment variables, such as wage rate and search costs, in light of factors including background differences of graduates, and market conditions such as the nursing shortage. Evidence suggests that the relative advantage enjoyed by the nursing group is associated with the additional human capital obtained through pursuing an academic concentration in nursing.

Chapter 13 - Biotechnological substances from fungi

Alexander Fleming's discovery of penicillin in 1928 revolutionized the treatment of infections, including those in dentistry. Nowadays, dentists are the second most common prescribers of antibiotics worldwide. However, inappropriate use has led to increased antimicrobial resistance (AMR), which is a growing global health issue. The World Health Organization has highlighted the impact of AMR on treatment efficacy, morbidity, mortality, and healthcare costs. During the coronavirus disease 2019 (COVID-19) pandemic, the misuse of antibiotics further exacerbated resistance, as unnecessary prescriptions and extended regimens diminished their effectiveness. Across Europe, excessive antibiotic use that is not aligned with guidelines has become common. Therefore, careful consideration is needed before prescribing antibiotics to minimize resistance risks. Our study aimed to evaluate the knowledge, attitudes, and practices (KAP) regarding antibiotic use and AMR among Albanian dentists. A cross-sectional survey was conducted among dentists in private clinics, academic staff, and dental students enrolled in specialization schools from November 2023 to April 2024. The study found high antibiotic prescription rates, often exceeding guidelines, with a significant proportion of dentists prescribing antibiotics every week. Common issues included overuse and inappropriate dosages, contributing to antibiotic resistance. The findings underline the need for improved AMR awareness and adherence to guidelines among Albanian dentists, emphasizing the necessity for updated education and better stewardship practices to combat antibiotic resistance.

The disputed discovery of streptomycin

If someone was to ask you to consider important advances in medicine, perhaps like me, you would think of Fleming's discovery of penicillin in the 1940s or the introduction of the portable defibrillator by Pantridge and team in the 1960s. I wonder if you would include today's health gadgets like the Fitbit.(1) Another, quieter gradual revolution is going on in Northern Ireland at the minute.(2),(3) When I started my Consultant career in 1995, it was quite commonplace for a query from a general practitioner to require access to the notes which might take about a month to arrive back with me from Medical Records (who knows what journey those notes went on). My answer to the query would then be dictated on to a cassette tape which would then join a row of similar tapes in a little plastic rack until my secretary reached the correct one. If the GP, frustrated by the delay, rang to find out what was happening, my secretary had to listen to the entire tape from the beginning to find the right segment. All of this seems faintly ludicrous some 20 years later, sitting in my home office, dictating into a desk microphone and watching these words appear a second later on my PC. The 6 Trusts in Northern Ireland are responsible for the healthcare of 1,800,000 people. Care is becoming more complex and often patients will attend more than one hospital site during their treatment. Many patients require intricate medication schedules which are changed frequently by general practitioner or hospital doctor. The “analogue era” of the 1990s can no longer meet our needs. The Northern Ireland Electronic Care Record project was initially mooted in 2005 as a solution to these problems. It was recognised that one Trust alone could not afford to develop the infrastructure required for a viable project. In 2008, site visits to innovative centres in the USA and Canada led to a regional ICT programme board approving a “proof of concept” trial involving case records in Belfast City Hospital, Ulster Hospital Dundonald and 2 large family practices. The project went “live” in January 2010. The aim of NIECR was to provide a single portal for viewing multiple sources of clinical information via a single logon to a single system which would eventually replace the multiplicity of laboratory, imaging, clinical and pharmacy applications that one must switch between to have a meaningful clinical encounter. Converting information held in isolated proprietary systems proved to be a major hurdle for NIECR but so far, more than 16 separate patient information systems have been incorporated into the dataset and there are plans to incorporate not only imaging reports but also the digital image files themselves. Consent to release of data and auditing of access formed a central part of the project with administrators able to review audit trails, especially in the setting of a “break the glass” privacy override. 5000 patient records were reviewed in the “proof of concept” phase. 78% of accesses were with full patient consent and 20% were with privacy overrides. 120 patients opted out of the system through their family practice – none opted out from a clinical setting. 74% of doctors surveyed felt that the new system led to a more rapid and correct diagnosis and 33% reported occasions when the system drew attention to a possible adverse event such as prescribing medication with a history of allergy. Following the successful evaluation phase, NIECR started rolling out across the province in 2012. The system works using a master patient index number based on a unique 10 digit “H&C” number – old hospital number prefixes like CAH, AH or RV are becoming relics of the past. Since roll-out, the system has become widely adopted throughout the province and the statistics are quite staggering:

All the world's a lab...at first, the graduate student

This article can rightly be called 'the rise of the microbial phoenix'; for, all the microbial infections whose doomsday was predicted with the discovery of antibiotics, have thumbed their noses at mankind and reemerged phoenix like. The hubris generated by Sir Alexander Fleming's discovery of Penicillin in 1928, exemplified best by the comment by William H Stewart, the US Surgeon General in 1967, "It is time to close the books on infectious diseases" has been replaced by the realisation that the threat of antibiotic resistance is, in the words of the Chief Medical Officer of England, Dame Sally Davies, "just as important and deadly as climate change and international terrorism". Antimicrobial resistance threatens to negate all the major medical advances of the last century because antimicrobial use is linked to many other fields like organ transplantation and cancer chemotherapy. Antibiotic resistance genes have been there since ancient times in response to naturally occurring antibiotics. Modern medicine has only driven further evolution of antimicrobial resistance by use, misuse, overuse and abuse of antibiotics. Resistant bacteria proliferate by natural selection when their drug sensitive comrades are removed by antibiotics. In this article the authors discuss the various causes of antimicrobial resistance and dwell in some detail on antibiotic resistance in gram-positive and gram-negative organisms. Finally they stress on the important role clinicians have in limiting the development and spread of antimicrobial resistance.

Since Fleming's discovery of penicillin nearly a century ago, a bounty of natural product antibiotics have been discovered, many of which continue to be of clinical importance today. The structural diversity encountered among nature's repertoire of antibiotics is mirrored by the varying mechanisms of action by which they selectively target and kill bacterial cells. The ability for bacteria to construct and maintain a strong cell wall is essential for their robust growth and survival under a range of conditions. However, the need to maintain the cell wall also presents a vulnerability that is exploited by many natural antibiotics. Bacterial cell wall biosynthesis involves both the construction of complex membrane-bound precursor molecules and their subsequent crosslinking by dedicated enzymes. Interestingly, many naturally occurring antibiotics function not by directly inhibiting the enzymes associated with cell wall biosynthesis, but rather by binding tightly to their membrane-bound substrates. Such substrate sequestration mechanisms are comparatively rare outside of the antibiotics space with most small-molecule drug discovery programs instead aimed at developing inhibitors of target enzymes. In this feature article we provide the reader with an overview of the unique and ever increasing family of natural product antibiotics known to specifically function by binding to membrane-anchored bacterial cell wall precursors. In doing so, we highlight both our own contributions to the field as well as those made by other researchers engaged in exploring the potential offered by antibiotics that target bacterial cell wall precursors.

Steve Ainsworth gives an overview of the key players and major developments in the history of hygiene from Jenner and his smallpox inoculation to Fleming's discovery of penicillin in the early 20th century.